Laboratory characteristics of granulomatous lymphocytic interstitial lung disease patients
| Laboratory characteristic | Acute steroid | Chronic MMF±corticosteroids | Immunoglobulin replacement |
| Serum immunoglobulin levels prior to period under study g·L−1 | |||
| IgG | 9.70 (8.30–10.40) | 8.00 (6.70–11.15) | 10.15 (6.60–14.38) |
| IgA | 0.05 (0.05–0.10) | 0.05 (0.05–0.50) | 0.05 (0.01–0.16) |
| IgM | 0.70 (0.50–1.30) | 0.70 (0.08–2.70) | 0.15 (0.06–0.28) |
| Trough immunoglobulin levels during period under study g·L−1 | |||
| IgG | 9.50 (8.93–11.60) | 10.70 (10.20–11.90) | 10.55 (10.05–12.70) |
| IgA | 0.05 (0.04–0.16) | 0.05 (0.05–0.50) | 0.05 (0.05–0.31) |
| IgM | 0.30 (0.16–0.90) | 0.30 (0.05–1.30) | 0.05 (0.05–0.24) |
| Lymphocyte subsets count prior to period under study ×109 per L | |||
| Lymphocyte count | 1.09 (0.85–1.21) | 1.32 (0.68–1.70) | 1.07 (0.72–2.03) |
| CD3 | 0.96 (0.82–1.01) | 1.01 (0.55–1.28) | 0.81 (0.55–1.33) |
| CD4 | 0.59 (0.35–0.73) | 0.44 (0.28–0.77) | 0.61 (0.42–0.71) |
| CD8 | 0.25 (0.20–0.42) | 0.35 (0.22–0.63) | 0.14 (0.09–0.76) |
| CD19 | 0.04 (0.02–0.09) | 0.20 (0.10–0.23) | 0.15 (0.10–0.39) |
| CD16+CD56 | 0.08 (0.03–0.38) | 0.08 (0.02–0.13) | 0.08 (0.05–0.12) |
| Lymphocyte subsets count during period under study ×109 per L | |||
| Lymphocyte count | 0.78 (0.43–1.17) | 1.13 (0.55–1.87) | 0.60 (0.28–1.13) |
| CD3 | 0.66 (0.39–0.98) | 0.88 (0.48–1.29) | 0.40 (0.19–0.93) |
| CD4 | 0.32 (0.22–0.65) | 0.43 (0.27–0.74) | 0.35 (0.18–0.38) |
| CD8 | 0.24 (0.18–0.29) | 0.29 (0.17–0.59) | 0.06 (0.03–0.51) |
| CD19 | 0.03 (0.01–0.06) | 0.16 (0.02–0.38) | 0.10 (0.03–0.16) |
| CD16+CD56 | 0.05 (0.02–0.11) | 0.06 (0.04–0.18) | 0.04 (0.02–0.06) |
| CVID EUROClass | |||
| smB+21Lo | 5 | 3# | |
| smB+21norm | 1 | 1 | |
| smB-21Lo | 2 | 3 | |
| B- | 1 | ||
Data are presented as median (interquartile range). MMF: mycophenolate mofetil; CVID: common variable immunodeficiency disorder. #: two patients were also in the acute steroid group.